← All drugs
Drug · FAERS side-effect profile with label screen

Fentanyl side effects: what 97,898 FDA adverse event reports show

Fentanyl · Fentanyl System · 1,215 reaction terms · 364,998 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Opioid Agonist

FDA label (Established Pharmacologic Class) · compare the class

Brand names

Fentanyl System

openFDA label

Who reports

97,898 reports · 85% serious · 27,747 with death outcome · 51% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid-tolerant patients, that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.

FDA label, Indications and Usage

What it is

The system contains fentanyl, an opioid agonist, for transdermal administration. The amount of fentanyl released from each system per hour is proportional to the surface area (25 mcg/hour per 9.44 cm 2 ). The composition per unit area of all transdermal system sizes is identical.

FDA label, Description section

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM . WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM See full prescribing information for complete boxed warning. Fentanyl transdermal system exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 1Labeled (related wording) 4Reporting / coding artifact 8Lab value / disease marker 4Not in label — unassessed 22
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,175 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Presbyacusis144185.8
148.5–232.5ROR 186.1 · calibrated p 1e-9 ✓
97.9 EB05 85.2 · IC025 +5.9
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=144 · ♀ 100% (drug 51%)no trial arm names this drug
Vaginal flatulence125148.5
118.2–186.8ROR 148.7 · calibrated p 8e-9 ✓
86.4 EB05 74.4 · IC025 +5.7
3/3 methods agree
vs other Opioid Agonists: PRR 1.3 (1.0–1.5)
Not in label — unassessedserious n=125 · ♀ 100% (drug 51%)no trial arm names this drug
Inspiratory capacity decreased99120.4
94.0–154.1ROR 120.5 · calibrated p 4e-8 ✓
75.8 EB05 64.1 · IC025 +5.5
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=99 · ♀ 0% (drug 51%) · 100% clinicianno trial arm names this drug
Anaesthetic complication neurological309110.0
95.9–126.2ROR 110.3 · calibrated p 6e-8 ✓
72.2 EB05 65.7 · IC025 +5.8
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=308 · ♀ 26% (drug 51%) · 100% clinicianno trial arm names this drug
Neuromuscular block prolonged11090.0
72.0–112.5ROR 90.1 · calibrated p 3e-7 ✓
62.7 EB05 53.5 · IC025 +5.3
3/3 methods agree
vs other Opioid Agonists: PRR 17.4 (10.7–28.3)
Not in label — unassessedserious n=106 · 100% clinicianno trial arm names this drug
Myoglobin urine present6473.6
55.3–97.8ROR 73.6 · calibrated p 2e-6 ✓
53.9 EB05 43.7 · IC025 +4.9
3/3 methods agree
vs other Opioid Agonists: only this drug
Lab value / disease markerserious n=63 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Maternal exposure during delivery23969.8
60.3–80.8ROR 70.0 · calibrated p 2e-6 ✓
52.5 EB05 47.1 · IC025 +5.4
3/3 methods agree
vs other Opioid Agonists: PRR 5.7 (4.6–7.1)
Reporting / coding artifactserious n=194 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Victim of homicide13466.5
54.7–80.7ROR 66.6 · calibrated p 3e-6 ✓
50.4 EB05 43.6 · IC025 +5.1
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=134 · ♀ 30% (drug 51%) · 100% consumerno trial arm names this drug
Delayed recovery from anaesthesia20458.6
50.2–68.4ROR 58.7 · calibrated p 5e-6 ✓
45.9 EB05 40.8 · IC025 +5.1
3/3 methods agree
vs other Opioid Agonists: PRR 19.7 (13.5–28.8)
Not in label — unassessedserious n=194 · 100% clinicianno trial arm names this drug
Counterfeit product administered24751.4
44.7–59.0ROR 51.5 · calibrated p 1e-5 ✓
41.4 EB05 37.2 · IC025 +5.1
3/3 methods agree
vs other Opioid Agonists: only this drug
Reporting / coding artifactserious n=242 · ♀ 29% (drug 51%) · 100% consumerno trial arm names this drug
Amnestic disorder8747.4
37.6–59.8ROR 47.4 · calibrated p 2e-5 ✓
38.6 EB05 32.2 · IC025 +4.6
3/3 methods agree
vs other Opioid Agonists: PRR 13.7 (8.4–22.6)
Not in label — unassessedserious n=85 · ♀ 0% (drug 51%) · 100% clinicianno trial arm names this drug
Opiates positive8646.1
36.5–58.3ROR 46.2 · calibrated p 3e-5 ✓
37.7 EB05 31.5 · IC025 +4.6
3/3 methods agree
vs other Opioid Agonists: PRR 19.8 (11.1–35.6)
Lab value / disease markerserious n=81 · ♀ 0% (drug 51%) · 100% clinicianno trial arm names this drug
Drug diversion98244.2
41.3–47.4ROR 44.7 · calibrated p 3e-5 ✓
36.7 EB05 34.8 · IC025 +5.1
3/3 methods agree
vs other Opioid Agonists: PRR 4.4 (4.0–4.8)
Reporting / coding artifactserious n=446 · ♀ 23% (drug 51%) · 90% consumerno trial arm names this drug
Pleural thickening11242.0
34.3–51.4ROR 42.0 · calibrated p 5e-5 ✓
35.0 EB05 29.9 · IC025 +4.6
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=112 · ♀ 100% (drug 51%)no trial arm names this drug
Product counterfeit26840.6
35.6–46.2ROR 40.7 · calibrated p 5e-5 ✓
34.1 EB05 30.8 · IC025 +4.8
3/3 methods agree
vs other Opioid Agonists: PRR 25.9 (17.9–37.6)
Reporting / coding artifactserious n=81 · ♀ 19% (drug 51%) · 100% consumerno trial arm names this drug
Pleural fibrosis16440.4
34.2–47.8ROR 40.5 · calibrated p 5e-5 ✓
34.0 EB05 29.8 · IC025 +4.7
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=164 · ♀ 100% (drug 51%)no trial arm names this drug
Procedural hypotension12235.4
29.3–42.9ROR 35.5 · calibrated p 1e-4 ✓
30.3 EB05 26.1 · IC025 +4.5
3/3 methods agree
vs other Opioid Agonists: PRR 13.6 (8.9–20.6)
Not in label — unassessedserious n=117 · 100% clinicianno trial arm names this drug
Blood magnesium increased12534.3
28.4–41.4ROR 34.3 · calibrated p 1e-4 ✓
29.5 EB05 25.4 · IC025 +4.4
3/3 methods agree
vs other Opioid Agonists: only this drug
Lab value / disease markerserious n=125 · ♀ 100% (drug 51%)no trial arm names this drug
Propofol infusion syndrome9432.8
26.4–40.7ROR 32.8 · calibrated p 2e-4 ✓
28.4 EB05 23.9 · IC025 +4.3
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=94 · ♀ 0% (drug 51%) · 100% clinicianno trial arm names this drug
Drug abuse10,77031.6
31.0–32.2ROR 35.3 · calibrated p 1e-4 ✓
27.6 EB05 27.1 · IC025 +4.8
3/3 methods agree
vs other Opioid Agonists: PRR 3.9 (3.8–4.0)
Reporting / coding artifactage-adj. PRR 28.0 · serious PRR 18.8 · ♀ 29% (drug 51%) · 91% clinicianno trial arm names this drug
Hypermobility syndrome6029.4
22.5–38.5ROR 29.4 · calibrated p 4e-4 ✓
25.7 EB05 20.7 · IC025 +4.0
3/3 methods agree
vs other Opioid Agonists: PRR 18.0 (9.2–35.2)
Not in label — unassessedserious n=60 · ♀ 100% (drug 51%)no trial arm names this drug
Foetal exposure during delivery8028.2
22.4–35.7ROR 28.3 · calibrated p 4e-4 ✓
24.9 EB05 20.6 · IC025 +4.1
3/3 methods agree
vs other Opioid Agonists: PRR 24.0 (12.4–46.3)
Reporting / coding artifactserious n=80 · 100% clinicianno trial arm names this drug
Bradycardia foetal8926.0
20.9–32.4ROR 26.1 · calibrated p 6e-4 ✓
23.2 EB05 19.4 · IC025 +4.0
3/3 methods agree
vs other Opioid Agonists: PRR 24.3 (13.0–45.4)
Not in label — unassessedserious n=85 · 100% clinicianno trial arm names this drug
Homicide18524.4
20.9–28.4ROR 24.4 · calibrated p 8e-4 ✓
21.9 EB05 19.4 · IC025 +4.1
3/3 methods agree
vs other Opioid Agonists: PRR 11.3 (8.3–15.5)
Not in label — unassessedserious n=77 · ♀ 27% (drug 51%) · 100% consumerno trial arm names this drug
Local anaesthetic systemic toxicity10524.1
19.7–29.4ROR 24.1 · calibrated p 9e-4 ✓
21.6 EB05 18.4 · IC025 +4.0
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=105 · 100% clinicianno trial arm names this drug
Female genital tract fistula15320.8
17.6–24.6ROR 20.8 · calibrated p 0.002 ✓
19.0 EB05 16.6 · IC025 +3.9
3/3 methods agree
vs other Opioid Agonists: PRR 1.3 (1.1–1.6)
Not in label — unassessedserious n=152 · ♀ 100% (drug 51%)no trial arm names this drug
Inadequate analgesia65717.7
16.3–19.2ROR 17.8 · calibrated p 0.003 ✓
16.4 EB05 15.4 · IC025 +3.9
3/3 methods agree
vs other Opioid Agonists: PRR 4.0 (3.5–4.5)
Reporting / coding artifactserious n=196no trial arm names this drug
Respiratory depression92017.3
16.2–18.5ROR 17.5 · calibrated p 0.004 ✓
16.1 EB05 15.2 · IC025 +3.9
3/3 methods agree
vs other Opioid Agonists: PRR 1.7 (1.5–1.8)
Labeled — boxed warning
exact term
age-adj. PRR 13.9 · serious PRR 10.9no trial arm names this drug
Osteosclerosis11516.8
13.9–20.3ROR 16.8 · calibrated p 0.005 ✓
15.6 EB05 13.3 · IC025 +3.6
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=115 · ♀ 100% (drug 51%)no trial arm names this drug
Anaesthetic complication19216.5
14.3–19.1ROR 16.5 · calibrated p 0.005 ✓
15.4 EB05 13.6 · IC025 +3.7
3/3 methods agree
vs other Opioid Agonists: PRR 12.3 (8.9–16.9)
Reporting / coding artifactserious n=164 · 100% clinicianno trial arm names this drug
Bone cyst6616.1
12.5–20.7ROR 16.1 · calibrated p 0.006 ✓
14.9 EB05 12.1 · IC025 +3.4
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=64 · ♀ 100% (drug 51%) · 100% clinicianno trial arm names this drug
Serotonin syndrome1,31815.8
14.9–16.7ROR 16.0 · calibrated p 0.005 ✓
14.8 EB05 14.1 · IC025 +3.8
3/3 methods agree
vs other Opioid Agonists: PRR 6.3 (5.8–7.0)
Labeled adverse reaction
exact term
age-adj. PRR 13.5 · serious PRR 10.0 · 93% clinicianno trial arm names this drug
Drug specific antibody9415.8
12.8–19.5ROR 15.8 · calibrated p 0.006 ✓
14.7 EB05 12.3 · IC025 +3.4
3/3 methods agree
vs other Opioid Agonists: only this drug
Lab value / disease markerserious n=94 · ♀ 100% (drug 51%) · 100% consumerno trial arm names this drug
Radiculopathy17915.5
13.3–18.1ROR 15.6 · calibrated p 0.006 ✓
14.5 EB05 12.8 · IC025 +3.6
3/3 methods agree
vs other Opioid Agonists: PRR 1.4 (1.1–1.6)
Not in label — unassessedserious n=178 · ♀ 100% (drug 51%)no trial arm names this drug
Systemic infection11115.2
12.6–18.5ROR 15.3 · calibrated p 0.007 ✓
14.2 EB05 12.1 · IC025 +3.4
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=111 · 100% clinicianno trial arm names this drug
Non-cardiogenic pulmonary oedema6914.8
11.6–18.9ROR 14.8 · calibrated p 0.008 ✓
13.8 EB05 11.2 · IC025 +3.3
3/3 methods agree
vs other Opioid Agonists: only this drug
Not in label — unassessedserious n=68 · ♀ 0% (drug 51%) · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal8,5776.46.2–6.5signal
Anaphylaxis / angioedema1,9373.33.2–3.5signal
Kidney injury4,5992.22.1–2.2signal
Rhabdomyolysis / myopathy8012.12.0–2.3raised
Suicidality2,1491.91.8–2.0raised
Arrhythmia / qt1,6881.91.8–2.0raised
Anaemia2,4111.71.7–1.8raised
Hyponatraemia5941.61.5–1.7raised
Depression1,9751.51.4–1.6raised
Thrombocytopenia1,5431.51.4–1.6raised
Serious infection5,3931.51.5–1.5raised
Gi bleeding1,2441.51.4–1.5raised
Seizure1,3301.51.4–1.5raised
Severe cutaneous reaction4821.41.3–1.5raised
Extrapyramidal6651.41.3–1.5raised
Neutropenia / agranulocytosis1,5451.31.3–1.4raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Fentanyl only as a background or rescue medication (NCT02625181, NCT00699335); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug abuse10,77031.6
31.0–32.2ROR 35.3 · calibrated p 1e-4 ✓
27.6 EB05 27.1 · IC025 +4.8
3/3 methods agree
vs other Opioid Agonists: PRR 3.9 (3.8–4.0)
Reporting / coding artifactage-adj. PRR 28.0 · serious PRR 18.8 · ♀ 29% (drug 51%) · 91% clinicianno trial arm names this drug
Pain7,3112.6
2.5–2.6ROR 2.7 · calibrated p 0.736
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
vs other Opioid Agonists: PRR 0.8 (0.8–0.8)
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.7 · serious PRR 2.4no trial arm names this drug
Drug dependence6,0968.3
8.1–8.5ROR 8.8 · calibrated p 0.050 ✓
8.0 EB05 7.9 · IC025 +3.0
3/3 methods agree
vs other Opioid Agonists: PRR 0.5 (0.5–0.5)
Reporting / coding artifactage-adj. PRR 8.0 · serious PRR 5.5 · 80% consumerno trial arm names this drug
Toxicity to various agents6,0418.0
7.8–8.2ROR 8.4 · calibrated p 0.057
7.7 EB05 7.5 · IC025 +2.9
3/3 methods agree
vs other Opioid Agonists: PRR 1.0 (1.0–1.1)
Not in label — unassessedage-adj. PRR 7.2 · serious PRR 5.3no trial arm names this drug
Drug ineffective (drug did not work)5,8260.9
0.9–1.0ROR 0.9 · calibrated p 0.271
0.9 EB05 0.9 · IC025 -0.1
PRR-only: not supported by EBGM or IC
vs other Opioid Agonists: PRR 1.6 (1.6–1.7)
Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.2no trial arm names this drug
Overdose5,8265.9
5.7–6.0ROR 6.2 · calibrated p 0.137
5.8 EB05 5.6 · IC025 +2.5
3/3 methods agree
vs other Opioid Agonists: PRR 0.6 (0.6–0.6)
Reporting / coding artifactage-adj. PRR 4.5 · serious PRR 4.8no trial arm names this drug
Death5,4721.4
1.3–1.4ROR 1.4 · calibrated p 0.565
1.4 EB05 1.3 · IC025 +0.4
vs other Opioid Agonists: PRR 0.7 (0.7–0.7)
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 1.5 · serious PRR 0.9no trial arm names this drug
Nausea5,1701.4
1.4–1.4ROR 1.4 · calibrated p 0.594
1.4 EB05 1.4 · IC025 +0.4
vs other Opioid Agonists: PRR 1.3 (1.3–1.3)
Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.5no trial arm names this drug
Vomiting3,7751.7
1.7–1.8ROR 1.8 · calibrated p 0.806
1.7 EB05 1.7 · IC025 +0.7
vs other Opioid Agonists: PRR 1.3 (1.2–1.3)
Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.5no trial arm names this drug
Fatigue (tiredness)3,5771.0
1.0–1.0ROR 1.0 · calibrated p 0.297
1.0 EB05 1.0 · IC025 -0.1
PRR-only: not supported by EBGM or IC
vs other Opioid Agonists: PRR 1.3 (1.2–1.3)
Labeled adverse reaction
exact term
age-adj. PRR 0.9 · serious PRR 1.0no trial arm names this drug
Off label use (used outside approved label)3,4400.8
0.8–0.9ROR 0.8 · calibrated p 0.208
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
vs other Opioid Agonists: PRR 1.3 (1.3–1.4)
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.9no trial arm names this drug
Dyspnoea (shortness of breath)3,0261.1
1.1–1.2ROR 1.2 · calibrated p 0.407
1.1 EB05 1.1 · IC025 +0.1
vs other Opioid Agonists: PRR 1.3 (1.3–1.4)
Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.0no trial arm names this drug
Drug withdrawal syndrome3,0227.5
7.3–7.8ROR 7.7 · calibrated p 0.074
7.3 EB05 7.1 · IC025 +2.8
3/3 methods agree
vs other Opioid Agonists: PRR 0.6 (0.6–0.6)
Labeled adverse reaction
exact term
age-adj. PRR 6.5 · serious PRR 5.7no trial arm names this drug
Hypotension (low blood pressure)3,0053.2
3.1–3.4ROR 3.3 · calibrated p 0.532
3.2 EB05 3.1 · IC025 +1.6
3/3 methods agree
vs other Opioid Agonists: PRR 2.0 (1.9–2.1)
Labeled adverse reaction
exact term
age-adj. PRR 3.2 · serious PRR 2.5no trial arm names this drug
Diarrhoea (diarrhea)2,9931.0
1.0–1.0ROR 1.0 · calibrated p 0.304
1.0 EB05 1.0 · IC025 -0.1
PRR-only: not supported by EBGM or IC
vs other Opioid Agonists: PRR 1.3 (1.2–1.4)
Labeled adverse reaction
exact term
age-adj. PRR 0.9 · serious PRR 1.0no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Fentanyl (opioids) ↔ Respiratory depression.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Fentanyl?

In FDA FAERS, the most frequently co-reported reaction terms for Fentanyl are pain, toxicity to various agents, nausea, vomiting, fatigue, dyspnoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Fentanyl have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM . WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF FENTANYL TRANSDERMAL SYSTEM See full prescribing information for complete boxed warning. Fentanyl transdermal system exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.

Do FAERS signals prove that Fentanyl causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.